Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2025)

Mirum Pharmaceuticals has reported EBITDA Margin over the past 5 years, most recently at 3.07% for Q4 2025.

  • Quarterly results put EBITDA Margin at 3.07% for Q4 2025, up 2130.0% from a year ago — trailing twelve months through Dec 2025 was 4.25% (up 2176.0% YoY), and the annual figure for FY2025 was 4.25%, up 2176.0%.
  • EBITDA Margin for Q4 2025 was 3.07% at Mirum Pharmaceuticals, down from 1.96% in the prior quarter.
  • Over the last five years, EBITDA Margin for MIRM hit a ceiling of 1.96% in Q3 2025 and a floor of 1452.36% in Q4 2021.
  • Median EBITDA Margin over the past 5 years was 52.69% (2023), compared with a mean of 197.72%.
  • Biggest five-year swings in EBITDA Margin: surged 132994bps in 2022 and later soared 1599bps in 2025.
  • Mirum Pharmaceuticals' EBITDA Margin stood at 1452.36% in 2021, then soared by 92bps to 122.41% in 2022, then surged by 62bps to 46.85% in 2023, then skyrocketed by 48bps to 24.36% in 2024, then skyrocketed by 87bps to 3.07% in 2025.
  • The last three reported values for EBITDA Margin were 3.07% (Q4 2025), 1.96% (Q3 2025), and 3.9% (Q2 2025) per Business Quant data.